Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.